These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 21526355

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH.
    Clin Cancer Res; 2009 Jun 15; 15(12):4207-12. PubMed ID: 19509177
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
    Polastro L, Aftimos PG, Awada A.
    Expert Rev Anticancer Ther; 2014 Jun 15; 14(6):649-65. PubMed ID: 24852360
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
    Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR.
    J Thorac Oncol; 2012 Mar 15; 7(3):574-8. PubMed ID: 22198425
    [Abstract] [Full Text] [Related]

  • 10. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
    Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, LeBlanc M, Urba SG.
    Invest New Drugs; 2011 Apr 15; 29(2):352-9. PubMed ID: 19937365
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
    Cortes J, Montero AJ, Glück S.
    Cancer Treat Rev; 2012 Apr 15; 38(2):143-51. PubMed ID: 21550727
    [Abstract] [Full Text] [Related]

  • 14. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C, Frenel JS, Campone M.
    Expert Opin Pharmacother; 2011 Dec 15; 12(18):2883-90. PubMed ID: 22087618
    [Abstract] [Full Text] [Related]

  • 15. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL.
    Clin Ther; 2012 Jul 15; 34(7):1467-73. PubMed ID: 22739019
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Ortega V, Antón A, Garau I, Afonso N, Calvo L, Fernández Y, Martínez-García M, Blanco E, Zamora P, García M, Illarramendi JJ, Rodríguez Sánchez CA, Sampayo M, Aguirre E, Pérez-García JM, Cortés J, Llombart-Cussac A.
    Clin Breast Cancer; 2019 Apr 15; 19(2):105-112. PubMed ID: 30679100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.